Varilrix Injection
Varilrix Injection is a live attenuated varicella (chickenpox) vaccine developed by GlaxoSmithKline. It is designed for the active immunization of individuals aged 12 months and above to prevent varicella infection. Administered subcutaneously, it is effective in reducing the severity or entirely preventing chickenpox when given in a two-dose schedule.
Contact us for sales assistance from our Biomedical Engineer.
Features:
-
Live Attenuated Vaccine: Contains weakened varicella-zoster virus to stimulate an immune response.
-
Two-Dose Schedule: Recommended for full protection against chickenpox.
-
High Immunogenicity: Proven efficacy in both children and adults.
-
Subcutaneous Administration: Minimally invasive and suitable for pediatric use.
-
Trusted Brand: Manufactured by GlaxoSmithKline (GSK), a globally recognized pharmaceutical company.
-
Ready-to-Use Diluent: Supplied with pre-filled syringe for ease of administration.
| Technical Specification |
|
|---|
- 1 Vial
-
Provides long-term immunity against chickenpox
-
Reduces complications from varicella infection (e.g., pneumonia, encephalitis)
-
Ideal for high-risk individuals and close contacts
-
Easy subcutaneous delivery suitable for infants and adults
-
Minimal side effects and good safety profile
-
Supports national immunization programs
